vs
Side-by-side financial comparison of Tapestry, Inc. (TPR) and Viatris (VTRS). Click either name above to swap in a different company.
Viatris is the larger business by last-quarter revenue ($3.7B vs $1.9B, roughly 1.9× Tapestry, Inc.). On growth, Tapestry, Inc. posted the faster year-over-year revenue change (21.0% vs 5.0%). Over the past eight quarters, Tapestry, Inc.'s revenue compounded faster (9.9% CAGR vs 0.5%).
Tapestry, Inc. is a leading American multinational luxury fashion holding company. It owns three iconic lifestyle brands: Coach, Kate Spade New York, and Stuart Weitzman, offering premium handbags, apparel, footwear, accessories, and fragrances to global consumers via physical retail stores and e-commerce platforms.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
TPR vs VTRS — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9B | $3.7B |
| Net Profit | $343.8M | — |
| Gross Margin | 76.9% | 31.1% |
| Operating Margin | 22.3% | -5.2% |
| Net Margin | 17.9% | — |
| Revenue YoY | 21.0% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $1.65 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.9B | — | ||
| Q4 25 | $2.5B | $3.7B | ||
| Q3 25 | $1.7B | $3.7B | ||
| Q2 25 | $1.7B | $3.6B | ||
| Q1 25 | $1.6B | $3.2B | ||
| Q4 24 | $2.2B | $3.5B | ||
| Q3 24 | $1.5B | $3.7B | ||
| Q2 24 | $1.6B | $3.8B |
| Q1 26 | $343.8M | — | ||
| Q4 25 | $561.3M | — | ||
| Q3 25 | $274.8M | — | ||
| Q2 25 | $-517.1M | — | ||
| Q1 25 | $203.3M | — | ||
| Q4 24 | $310.4M | — | ||
| Q3 24 | $186.6M | — | ||
| Q2 24 | $159.3M | — |
| Q1 26 | 76.9% | — | ||
| Q4 25 | 75.5% | 31.1% | ||
| Q3 25 | 76.3% | 36.6% | ||
| Q2 25 | 76.3% | 37.3% | ||
| Q1 25 | 76.1% | 35.8% | ||
| Q4 24 | 74.4% | 34.6% | ||
| Q3 24 | 75.3% | 39.0% | ||
| Q2 24 | 74.9% | 38.2% |
| Q1 26 | 22.3% | — | ||
| Q4 25 | 28.6% | -5.2% | ||
| Q3 25 | 19.3% | 4.8% | ||
| Q2 25 | -33.9% | 6.5% | ||
| Q1 25 | 16.0% | -88.9% | ||
| Q4 24 | 22.4% | -5.1% | ||
| Q3 24 | 16.7% | 6.0% | ||
| Q2 24 | 14.8% | -6.3% |
| Q1 26 | 17.9% | — | ||
| Q4 25 | 22.4% | — | ||
| Q3 25 | 16.1% | — | ||
| Q2 25 | -30.0% | — | ||
| Q1 25 | 12.8% | — | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 12.4% | — | ||
| Q2 24 | 10.0% | — |
| Q1 26 | $1.65 | — | ||
| Q4 25 | $2.68 | $-0.34 | ||
| Q3 25 | $1.28 | $-0.11 | ||
| Q2 25 | $-2.30 | $0.00 | ||
| Q1 25 | $0.95 | $-2.55 | ||
| Q4 24 | $1.38 | $-0.43 | ||
| Q3 24 | $0.79 | $0.08 | ||
| Q2 24 | $0.67 | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $1.3B |
| Total DebtLower is stronger | $2.4B | — |
| Stockholders' EquityBook value | $682.4M | $14.7B |
| Total Assets | $6.5B | $37.2B |
| Debt / EquityLower = less leverage | 3.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $743.2M | $975.3M | ||
| Q2 25 | $1.1B | $566.4M | ||
| Q1 25 | $1.1B | $755.0M | ||
| Q4 24 | $1.0B | $734.8M | ||
| Q3 24 | $7.3B | $1.9B | ||
| Q2 24 | $7.2B | $917.2M |
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $7.0B | — | ||
| Q2 24 | $6.9B | — |
| Q1 26 | $682.4M | — | ||
| Q4 25 | $551.2M | $14.7B | ||
| Q3 25 | $399.5M | $15.2B | ||
| Q2 25 | $857.8M | $15.6B | ||
| Q1 25 | $1.5B | $15.7B | ||
| Q4 24 | $1.3B | $18.6B | ||
| Q3 24 | $3.0B | $19.8B | ||
| Q2 24 | $2.9B | $19.5B |
| Q1 26 | $6.5B | — | ||
| Q4 25 | $6.5B | $37.2B | ||
| Q3 25 | $6.4B | $37.9B | ||
| Q2 25 | $6.6B | $38.4B | ||
| Q1 25 | $7.3B | $38.5B | ||
| Q4 24 | $7.3B | $41.5B | ||
| Q3 24 | $13.7B | $44.8B | ||
| Q2 24 | $13.4B | $45.3B |
| Q1 26 | 3.48× | — | ||
| Q4 25 | 4.32× | — | ||
| Q3 25 | 5.95× | — | ||
| Q2 25 | 2.77× | — | ||
| Q1 25 | 1.59× | — | ||
| Q4 24 | 1.78× | — | ||
| Q3 24 | 2.35× | — | ||
| Q2 24 | 2.39× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $815.8M |
| Free Cash FlowOCF − Capex | — | $619.3M |
| FCF MarginFCF / Revenue | — | 16.8% |
| Capex IntensityCapex / Revenue | — | 5.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $815.8M | ||
| Q3 25 | $112.6M | $744.9M | ||
| Q2 25 | $446.8M | $219.7M | ||
| Q1 25 | $144.3M | $535.5M | ||
| Q4 24 | $506.0M | $482.7M | ||
| Q3 24 | $119.5M | $826.5M | ||
| Q2 24 | $256.0M | $379.1M |
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $619.3M | ||
| Q3 25 | $80.2M | $658.1M | ||
| Q2 25 | $411.5M | $166.8M | ||
| Q1 25 | $113.4M | $492.9M | ||
| Q4 24 | $475.1M | $342.3M | ||
| Q3 24 | $93.9M | $749.5M | ||
| Q2 24 | $209.8M | $320.3M |
| Q1 26 | — | — | ||
| Q4 25 | 41.5% | 16.8% | ||
| Q3 25 | 4.7% | 17.6% | ||
| Q2 25 | 23.9% | 4.7% | ||
| Q1 25 | 7.2% | 15.2% | ||
| Q4 24 | 21.6% | 9.7% | ||
| Q3 24 | 6.2% | 20.1% | ||
| Q2 24 | 13.2% | 8.5% |
| Q1 26 | — | — | ||
| Q4 25 | 1.7% | 5.3% | ||
| Q3 25 | 1.9% | 2.3% | ||
| Q2 25 | 2.0% | 1.5% | ||
| Q1 25 | 2.0% | 1.3% | ||
| Q4 24 | 1.4% | 4.0% | ||
| Q3 24 | 1.7% | 2.1% | ||
| Q2 24 | 2.9% | 1.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.93× | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 1.61× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TPR
Segment breakdown not available.
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
